advertisement
Sonoda KH 31
Showing records 1 to 25 | Display all abstracts from Sonoda KH95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Arima M
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Terada Y; Kaburaki T
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Inoue H; Nakao S
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Takase H; Goto H
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Misumi A
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Nakano S
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Suzuki M
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Inoue Y
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Matsushita I
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Maruyama K
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Araki S; Yamashiro C
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Miyata K; Namba K
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Takahashi K
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Namba K
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Ochiai M
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Sonoda KH; Kaneko Y
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Yoshida N; Hirose M
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Numaga J
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Kishimoto J
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Fukushima M
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Todaka K
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Horiguchi N; Ide M
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Hasegawa S
BMJ open 2021; 11: e047003
95525 Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus
Ehara F
American Journal of Ophthalmology 2021; 227: 191-200
95522 Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Kimura K
BMJ open 2021; 11: e047003
